Arrowhead Pharmaceuticals, Inc. (ARWR)
NASDAQ: ARWR · Real-Time Price · USD
74.52
+0.11 (0.15%)
At close: Jun 12, 2026, 4:00 PM EDT
74.51
-0.01 (-0.01%)
After-hours: Jun 12, 2026, 6:35 PM EDT
Arrowhead Pharmaceuticals Balance Sheet
Financials in millions USD. Fiscal year is October - September.
Millions USD. Fiscal year is Oct - Sep.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 |
Cash & Equivalents | 147.53 | 88.71 | 76.21 | 110.89 | 108.01 | 184.43 |
Short-Term Investments | - | 692.41 | 578.28 | 292.74 | 268.39 | 183.36 |
Cash & Short-Term Investments | 147.53 | 781.12 | 654.48 | 403.63 | 376.4 | 367.79 |
Cash Growth | -86.56% | 19.35% | 62.15% | 7.23% | 2.34% | 16.58% |
Accounts Receivable | 15.69 | 4.82 | - | - | 1.41 | 10.26 |
Other Current Assets | 80.96 | 162.29 | 40.99 | 12.85 | 27.49 | 6.55 |
Total Current Assets | 1,840 | 950.64 | 695.47 | 416.47 | 405.3 | 384.6 |
Net Property, Plant & Equipment | 417.62 | 346.01 | 431.56 | 335.56 | 168.59 | 66.02 |
Other Intangible Assets | 6.01 | 2.86 | 2.56 | 10.26 | 11.96 | 13.66 |
Long-Term Investments | - | - | - | - | 105.87 | 245.6 |
Other Long-Term Assets | 4.89 | 1.39 | 4.48 | 3.26 | 0.22 | 0.27 |
Total Assets | 2,268 | 1,385 | 1,140 | 765.55 | 691.94 | 710.15 |
Accounts Payable | 30.75 | 17.67 | 11.39 | 35.87 | 2.87 | 9.46 |
Accrued Expenses | 96.95 | 117.31 | 85.01 | 57.73 | 59.11 | 23.77 |
Short-Term Debt | 40 | 40 | - | - | - | - |
Current Portion of Leases | 7.77 | 7.29 | 6.34 | 10.56 | 2.78 | 2.25 |
Unearned Revenue | 108.54 | 2.4 | - | 0.87 | 74.1 | 111.06 |
Other Current Liabilities | 11.21 | 10.81 | 0.43 | 0.44 | - | - |
Total Current Liabilities | 295.22 | 195.49 | 103.17 | 105.46 | 138.85 | 146.54 |
Long-Term Debt | 1,225 | 582.28 | 734.54 | 268.33 | - | - |
Long-Term Leases | 100.11 | 104.11 | 111.03 | 104.61 | 78.8 | 23.3 |
Other Long-Term Liabilities | 48.62 | - | - | - | 55.95 | 131.5 |
Total Long-Term Liabilities | 1,374 | 686.39 | 845.57 | 372.93 | 134.75 | 154.79 |
Total Liabilities | 1,669 | 881.88 | 948.74 | 478.39 | 273.6 | 301.33 |
Common Stock | 0.24 | 0.23 | 0.22 | 0.2 | 0.2 | 0.2 |
Treasury Stock | -53.19 | -53.19 | - | - | - | - |
Additional Paid-in Capital | 2,395 | 2,139 | 1,806 | 1,300 | 1,219 | 1,053 |
Accumulated Other Comprehensive Income | 0.74 | 4.44 | 2 | -3.22 | -0.14 | -0.07 |
Retained Earnings | -1,729 | -1,627 | -1,626 | -1,026 | -820.76 | -644.69 |
Total Common Shareholders' Equity | 613.98 | 463.5 | 182.69 | 271.34 | 398.52 | 408.82 |
Minority Interest | -15.06 | 20.42 | 8.37 | 15.82 | 19.82 | - |
Shareholders' Equity | 598.92 | 503.92 | 191.06 | 287.16 | 418.34 | 408.82 |
Total Liabilities & Equity | 2,268 | 1,385 | 1,140 | 765.55 | 691.94 | 710.15 |
Total Debt | 1,373 | 733.68 | 851.91 | 383.5 | 81.58 | 25.55 |
Net Cash (Debt) | -1,226 | 47.44 | -197.43 | 20.13 | 294.82 | 342.24 |
Net Cash Growth | - | - | - | -93.17% | -13.86% | 16.27% |
Net Cash Per Share | -8.80 | 0.35 | -1.65 | 0.19 | 2.80 | 3.30 |
Book Value | 613.98 | 463.5 | 182.69 | 271.34 | 398.52 | 408.82 |
Book Value Per Share | 4.41 | 3.47 | 1.53 | 2.54 | 3.78 | 3.94 |
Tangible Book Value | 607.97 | 460.64 | 180.13 | 261.08 | 386.56 | 395.16 |
Tangible Book Value Per Share | 4.36 | 3.44 | 1.50 | 2.45 | 3.67 | 3.81 |